Affiliation:
1. I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia;
N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of Russia;
N.P. Bochkov Research Centre for Medical Genetics
2. N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
3. I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia;
N.P. Bochkov Research Centre for Medical Genetics
Abstract
Improving the laboratory diagnosis of prostate cancer and bladder cancer are still an actual problem in modern urologic oncology. Test systems for DNA or RNA alterations that occurred during carcinogenesis and associated with the malignant tumor and the prognosis of disease have been actively developed in recent years. Here we reviewed the data published mainly in the last 5 years about the molecular genetic kits for diagnosis (Progensa, SelectMDx, ExoDx Prostate Test, Prosta-Test, Confirm MDx) and assessment of prognosis (Prolaris, Decipher, Oncotype DX) in patients with prostate cancer, discussed their sensitivity and specificity. The characteristics of analogous kits and panels for bladder cancer (UroVysion, CertNDx Bladder Cancer Assay, UroSEEK, mutations in the FGFR3 and TERT genes, and the Cxbladder Monitor/Detect/Triage kit's line) were systematized. Particularly we focused on the description of the patient cohorts for whom kits mentioned above have greater diagnostic accuracy, described limitations of these test systems in consequence both a methodological and registration aspects, and their use in combination with other tumor markers. This review is aimed at oncologists, urologists, laboratory geneticists and specialists in related professions.
Publisher
Publishing House ABV Press
Subject
Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference59 articles.
1. Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Oncourologiya = Cancer Urology 2019;15(2):15-24. (in Russ.). DOI: 10.17650/1726-9776-2019-15-2-15-24.
2. Chissov V.I., Alekseev B.Y., Rusakov I.G. М.: Geotar-Media, 2012, 688 pp. ISBN: 978-5-9704-2181-9.
3. Mikhaylenko D.S., Efremov G.D., Alekseev B.Y. Molecular genetic methods in diagnostics of hereditary and sporadic urological tumors. Spravochnik zaveduyuschego KLD = Handbook of the head of clinical laboratory 2016;2:38-46. (in Russ.).
4. Wu D., Ni J., Beretov J. et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol 2017;118:15-26. PMID: 28917266. DOI: 10.1016/j.critrevonc.2017.08.002.
5. Mikhailenko D.S., Kushlinskii N.E. The somatic mutations and aberrant methylation as potential genetic markers of urinary bladder cancer. Klinicheskaya laboratornaya diagnostica = Klin Lab Diagn 2016;61(2):78-83. (in Russ.). PMID: 27455559. DOI: 10.18821/0869-2084-2016-61-2-78-83.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献